The partners will further develop a test to guide clinical care of patients with Plasmodium vivax malaria who may also have G6PD deficiency.
The platform counts single target molecules in stool samples within 30 minutes and without sample preparation to detect C. diff. toxins.
The assay detects a mutation that can confer hearing loss in patients, particularly neonates, who have taken gentamicin, an antibiotic prescribed for certain bacterial infections.
The researchers used multiple-reaction monitoring mass spec to create a more sensitive assay to AFP-L3, a protein marker for hepatocellular carcinoma.
They found that cMyC protein was more abundant than cardiac troponin in heart disease patients and that it could be used to quickly rule out heart attack.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
The initial focus will be on Zika and chikingunya, and will leverage iBio's antigen and antibody manufacturing capabilities for product prototype development.
The company is now commencing a trial of the test platform in 250 patients to generate more data while it considers how to best commercialize it.
They have begun field testing near-infrared spectroscopy as an alternative to PCR and ELISA for routine pathogen screening in mosquitoes.
The company has partnered with several major medical centers to recruit several thousand subjects to compare its test to current mainstays.